A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Lenvatinib (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 09 Mar 2017 Status changed to recruiting.
- 06 Mar 2017 Status changed from recruiting to completed.
- 24 Feb 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.